NHS to Launch World-First AI Tool to Predict Type 2 Diabetes Risk
The NHS in England is set to launch a groundbreaking trial of an artificial
intelligence (AI) tool designed to predict the risk of type 2 diabetes up to
13 years before it develops. The innovative technology, known as Aire-DM,
analyzes electrocardiogram (ECG) readings during routine heart scans to
identify subtle changes that signal an increased risk of diabetes. These
patterns are often too small for the human eye to detect but reflect early
impacts of diabetes on the heart.
The trial, starting in 2025 at two London hospital trusts—Imperial College Healthcare NHS Trust and Chelsea and Westminster Hospital NHS Foundation Trust—marks a world-first in healthcare. Aire-DM, developed using data from 1.2 million ECGs and validated through the UK Biobank, has shown an accuracy rate of approximately 70% in predicting diabetes risk. When combined with clinical and genetic information, the tool's precision improves further.
Type 2 diabetes, a condition affecting over 500 million people worldwide, is linked to severe health complications such as heart disease, kidney failure, and blindness. Early detection through AI could enable timely interventions, including lifestyle changes, to prevent or delay the onset of the disease. If successful, Aire-DM could be rolled out across England's NHS and potentially globally, revolutionizing preventive healthcare.
No Comment to " NHS to Launch World-First AI Tool to Predict Type 2 Diabetes Risk "